Article Text

other Versions

Download PDFPDF
Non-invasive stereotactic ablative boost in patients with locally advanced cervical cancer
  1. Shraddha Dalwadi1,
  2. Alfredo Echeverria1,
  3. Pavan Jhaveri1,
  4. Tung Bui1,
  5. Nabila Waheed2,
  6. Danny Tran3,
  7. Mark Bonnen4 and
  8. Michelle Ludwig1
  1. 1Department of Radiation Oncology, Baylor College of Medicine, Houston, Texas, USA
  2. 2Department of Radiation Oncology, The Center for Cancer and Blood Disorders, Dallas, Texas, United States
  3. 3Department of Radiation Oncology, Remote Dosimetry Services, Houston, Texas, USA
  4. 4Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
  1. Correspondence to Dr Michelle Ludwig, Baylor College of Medicine, Houston, TX 77030, USA; Michelle.Ludwig{at}bcm.edu

Abstract

Introduction The current literature is insufficient to guide care for patients with cervical cancer ineligible for brachytherapy. Stereotactic ablative radiotherapy boost is a clinical necessity for these patients, but highly debated among radiation oncologists.

Objective To report toxicity and survival outcomes in a large cohort of patients with locally advanced cervical cancer treated with a non-invasive stereotactic ablative radiotherapy boost instead of brachytherapy

Methods Patients with locally advanced cervical cancer were entered, between January 2008 and December 2018, who were recommended definitive intent external boost after pelvic radiotherapy to 45–50.4 Gy concurrent with weekly cisplatin and simultaneous/sequential nodal boost up to 55–66 Gy. Simulation CT was facilitated using radio-opaque fiducials, empty rectum, dedicated bladder filling, and whole body vaculoplastic immobilization. Kaplan-Meier survival estimates were used to report local/regional recurrences, distant metastases, cancer-specific survival, and overall survival.

Results A total of 25 patients were analyzed. Median follow-up was 25 months (range 6–54). Patients received stereotactic ablative radiotherapy due to refusal of brachytherapy (9/25, 36%), medical co-morbidities limiting implantation (9/25, 36%), or technical infeasibility (7/25, 28%). Typical fractionation was 24–30 Gy in 4–5 fractions (24/25, 96%). The most common long-term toxicity was grade 1–2 vaginal dryness, discomfort, stenosis, and/or dyspareunia (4/25, 16%). One patient had new post-treatment grade 4 fistula in an area of previous tumor erosion (1/25, 4%). Overall survival, cancer specific survival, loco-regional control, and distant control were 95.5%, 100%, 95.5%, and 89.1%, respectively, at 2 years.

Conclusion Further study of stereotactic ablative radiotherapy boost for cervical cancer is needed; a brachytherapy-similar approach portends clinical success with 95.5% overall survival and loco-regional control at 2 years.

  • cervical cancer
  • radiation
  • brachytherapy
View Full Text

Statistics from Altmetric.com

Footnotes

  • Twitter @loveandmedicine

  • Contributors All authors contributed to this manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. No comparative or complex analyses were performed in this small series.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.